Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Kita R, et al. Among authors: sano y. Jpn J Clin Oncol. 2024 Dec 18:hyae174. doi: 10.1093/jjco/hyae174. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39690810
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE).
Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, Furuse J, Ozaka M, Fukuda H, Ueno M; Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group. Sano Y, et al. Jpn J Clin Oncol. 2024 Nov 2;54(11):1214-1218. doi: 10.1093/jjco/hyae084. Jpn J Clin Oncol. 2024. PMID: 38941345 Clinical Trial.
Study protocol: randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs. immediate surgery and adjuvant chemotherapy for localized soft tissue sarcoma: Japan Clinical Oncology Group study JCOG2102 (NACLESS).
Funauchi Y, Tsukushi S, Hiraga H, Sakamoto A, Kunisada T, Nagano A, Hiraoka K, Kikuta K, Yonemoto T, Ae K, Kawai A, Endo M, Sano Y, Machida R, Sekita T, Fukuda H, Oda Y, Ozaki T, Tanaka K; JCOG Bone Soft Tissue Tumor Study Group. Funauchi Y, et al. Among authors: sano y. Jpn J Clin Oncol. 2024 Nov 5:hyae160. doi: 10.1093/jjco/hyae160. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39500618
Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113.
Okuno T, Morizane C, Mizusawa J, Yanagimoto H, Kobayashi S, Imaoka H, Terashima T, Kawakami H, Sano Y, Okusaka T, Ikeda M, Ozaka M, Miwa H, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Sano K, Tobimatsu K, Katanuma A, Gotoh K, Yamaguchi H, Ishii H, Furuse J, Ueno M. Okuno T, et al. Among authors: sano k, sano y. Int J Clin Oncol. 2024 Oct 23. doi: 10.1007/s10147-024-02642-9. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39441453
Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
Hirano H, Kataoka K, Yamaguchi T, Wagner AD, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Mizusawa J, Sano Y, Shiomi A, Shiozawa M, Ohue M, Adachi T, Ueno H, Ikeda S, Komori K, Tsukamoto S, Takashima A, Kanemitsu Y. Hirano H, et al. Among authors: sano y. Eur J Cancer. 2025 Jan;214:115139. doi: 10.1016/j.ejca.2024.115139. Epub 2024 Nov 19. Eur J Cancer. 2025. PMID: 39579641
Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
Tozuka Y, Ueno M, Kobayashi S, Morimoto M, Fukushima T, Sano Y, Kawano K, Hanaoka A, Tezuka S, Asama H, Moriya S, Morinaga S, Ohkawa S, Maeda S. Tozuka Y, et al. Among authors: sano y. Oncol Lett. 2022 Sep 8;24(4):375. doi: 10.3892/ol.2022.13495. eCollection 2022 Oct. Oncol Lett. 2022. PMID: 36238838 Free PMC article.
Prognostic Relevance of Primary Tumor Sidedness in Early-stage Colorectal Cancer: An Integrated Analysis of 4 Randomized Controlled Trials (JCOG2003A).
Ouchi A, Sadachi R, Hamaguchi T, Tsukamoto S, Shimada Y, Inomata M, Takii Y, Komori K, Shiomi A, Shiozawa M, Ohue M, Watanabe J, Ito M, Kawashima Y, Kobatake T, Souda H, Saida Y, Hashimoto T, Sano Y, Kanemitsu Y; JCOG Colorectal Cancer Study Group. Ouchi A, et al. Among authors: sano y. Ann Surg. 2024 Feb 1;279(2):283-289. doi: 10.1097/SLA.0000000000006076. Epub 2023 Aug 8. Ann Surg. 2024. PMID: 37551612
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Tezuka S, Ueno M, Oishi R, Nagashima S, Sano Y, Kawano K, Tanaka S, Fukushima T, Asama H, Konno N, Kobayashi S, Morimoto M, Maeda S. Tezuka S, et al. Among authors: sano y. Cancer Med. 2022 Feb;11(4):1088-1098. doi: 10.1002/cam4.4512. Epub 2021 Dec 24. Cancer Med. 2022. PMID: 34953056 Free PMC article.
1,916 results